NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE241212 Query DataSets for GSE241212
Status Public on Oct 18, 2023
Title Nonfucosylation of an anti-TIGIT antibody enhances FcyR engagement, driving innate immune activation and antitumor activity
Organisms Homo sapiens; Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary TIGIT is an immune checkpoint receptor expressed on activated and memory T cells, immunosuppressive T regulatory cells, and natural killer (NK) cells. TIGIT has emerged as an attractive target for antitumor therapies, due to its proposed immunosuppressive effects on lymphocyte function and T cell activation. We generated an anti-TIGIT monoclonal antibody (mAb) that binds with high affinity to human, non-human primate, and murine TIGIT and through multiple experimental methodologies demonstrated that checkpoint blockade alone is insufficient for antitumor activity. Generating anti-TIGIT mAbs with various Fc backbones we show that muting the Fc-Fcγ receptor (FcγR) interaction failed to drive antitumor activity, while mAbs with Fc functional backbones demonstrate substantial antitumor activity, mediated through activation of antigen-presenting cells (APCs), T cell priming, and NK-mediated depletion of suppressive Tregs and exhausted T cells. Further, nonfucosylation of the Fc backbone resulted in enhanced immune responses and antitumor activity relative to the intact IgG1 backbone. The improved activity correlated with the biased FcγR interaction profile of the nonfucosylated anti-TIGIT mAb, which supports that FcγRIIIa binding with decreased FcγRIIb binding favorably activates APCs and enhances tumor-specific CD8+ T cell responses. The anti-TIGIT mAbs with intact FcγR interacting backbones also demonstrated synergistic enhancement of other standard antitumor treatments, including anti-PD-1 treatment and a model monomethyl auristatin E antibody–drug conjugate. These findings highlight the importance of the anti-TIGIT mAb’s Fc backbone to its antitumor activity and the extent to which this activity can be enhanced through nonfucosylation of the backbone
 
Overall design Bulk RNA-seq was performed on tumors from syngeneic mouse models, and gene-level transcript levels were subsequently used to compute immune-related gene signature scores that were correlated with the activity of SEA-TGT in those models.
 
Contributor(s) Smith AJ, Thurman RE, Gutierrez L
Citation(s) 38022590
Submission date Aug 18, 2023
Last update date Dec 01, 2023
Contact name Alyson J Smith
Organization name Seagen Inc.
Department Research
Street address 21717 30th Drive S.E., Building 3
City Bothell
State/province WA
ZIP/Postal code 98021
Country USA
 
Platforms (2)
GPL24247 Illumina NovaSeq 6000 (Mus musculus)
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Samples (47)
GSM7719458 Human Lung DTC rep 1 [Seagen]
GSM7719459 Human Lung DTC rep 2 [Seagen]
GSM7719460 Human Lung DTC rep 3 [Seagen]
Relations
BioProject PRJNA1006730

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE241212_barcodes.tsv.gz 83.4 Kb (ftp)(http) TSV
GSE241212_features.tsv.gz 312.6 Kb (ftp)(http) TSV
GSE241212_matrix.mtx.gz 89.1 Mb (ftp)(http) MTX
GSE241212_tpm.all.final.txt.gz 5.5 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap